Oncology (all articles) | Page 4 of 122 | Links Medicus Content Curation & Alerts in Medicine

Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone. Full results of CAPItello-291: https://t.co/ZCBHkG305b

— NEJM (@NEJM) May 31, 2023

RCT | Vorasidenib enhances PFS in IDH1/2-mutant low-grade glioma, trial methods debated online

7 Jun, 2023 | 14:04h | UTC

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Vorasidenib Delays Disease Progression or Death in Patients With Grade 2 IDH-Mutated Glioma – The ASCO Post

Commentary on Twitter questioning study methodology (thread – click for more)

This is a rather troubling study. The fact that it got published in @NEJM is concerning, to say the least

Astonishing cost of $16 000/month for a drug administered continuously until disease progression in a trial with a dubious endpoint and flawed design

Here are my thoughts: https://t.co/E3QtZfEyQw

— Stanislav (Stas) Lazarev, MD (@StasLazarev) June 5, 2023

RCT | Atezolizumab and cabozantinib combo fails to outperform cabozantinib alone in renal cell carcinoma

7 Jun, 2023 | 13:54h | UTC

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial – The Lancet (free registration required)

Commentary from the author on Twitter (thread – click for more)

1/ Results from #CONTACT03 are out both @ASCO #ASCO23 and @TheLancet . The 1⃣st phase 3 trial to assess the efficacy of rechallenge with anti-PDL1 in ANY cancer type.
Kudos to @montypal, SC members, @roche, our patients, = for this phenomenal job. https://t.co/p7hYD4snXA pic.twitter.com/CXk1vqfB26

— Toni Choueiri, MD (@DrChoueiri) June 5, 2023

RCT | Adding dalpiciclib to standard letrozole or anastrozole treatment outperforms placebo in HR+, HER2- advanced breast cancer

7 Jun, 2023 | 13:44h | UTC

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Dalpiciclib Combo Improves PFS Vs Placebo in HER2– Advanced Breast Cancer – Cancer Network

RCT | Perioperative pembrolizumab improves pathological outcomes, event-free survival in early-stage NSCLC

6 Jun, 2023 | 14:36h | UTC

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

Presented at #ASCO23: In the KEYNOTE-671 trial, pts with resectable lung cancer were assigned to neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo. Two-year event-free survival was 62.4% with pembrolizumab & 40.6% with placebo.

— NEJM (@NEJM) June 3, 2023

RCT | Befotertinib tops Icotinib in NSCLC progression-free survival, but increases serious adverse events

6 Jun, 2023 | 14:13h | UTC

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

M-A | Robot-assisted radical cystectomy versus open radical cystectomy

6 Jun, 2023 | 14:11h | UTC

Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials – European Urology

Commentary from the author on Twitter (thread – click for more)

Our meta-analysis of 8 RCTS comparing open (ORC) and robot-assisted radical cystectomy (RARC) is now online on @EUplatinum 1/6https://t.co/b9TYe2yd9Y @JimCatto @Jkurol @drtanws @DrTanWP @SWilliams_MD @SBoorjian @roboturoloog @dipenjparekh @nikhilvasdevuro @ProfShamimKhan1 pic.twitter.com/M4u0iXTuwN

— Pramit Khetrapal (@p_khetrapal) May 10, 2023

Review | Patient-centered care in the management of cancer during pregnancy

6 Jun, 2023 | 14:10h | UTC

Patient-Centered Care in the Management of Cancer During Pregnancy – ASCO Educational Book

See other articles in the series: 2023 ASCO Educational Book

RCT | Noninferiority shown between DOACs and LMWH for recurrent VTE prevention in cancer patients

5 Jun, 2023 | 13:50h | UTC

Summary: This unblinded, pragmatic, noninferiority randomized clinical trial aimed to assess the efficacy of direct oral anticoagulants (DOACs) against low-molecular-weight heparin (LMWH) in preventing recurrent venous thromboembolism (VTE) in patients with cancer. The study included 671 patients from 67 oncology centers, with a new clinical or radiological diagnosis of VTE.

Participants were randomly assigned to receive either a DOAC or LMWH for 6 months, and treating physicians selected and prescribed the drugs based on considerations like availability and drug-drug interactions. The primary outcome was the rate of recurrent VTE at 6 months. Findings revealed that the DOAC group had a recurrent VTE rate of 6.1% as compared to 8.8% in the LMWH group, showing noninferiority. Both groups had statistically similar rates of major bleeding and severe adverse events.

This pragmatic study included patients with advanced cancer and brain metastases, impaired performance status, and reduced liver or kidney function, making it more representative of routine oncology practice. Moreover, patient adherence to DOAC treatment was significantly higher than to LMWH. Nevertheless, the study had limitations, including the lack of blinding and underrepresentation of certain racial and ethnic groups.

In conclusion, this trial suggests that DOACs were noninferior to LMWH for preventing recurrent VTE in patients with cancer over a 6-month follow-up period, supporting the use of DOACs in this population for VTE prevention. Further research is needed to confirm these results and investigate long-term outcomes.

Article: Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)

See also: Visual abstract

Commentary on Twitter

Among adults with cancer and VTE, direct oral anticoagulants were noninferior to low-molecular-weight heparin for preventing recurrent VTE over 6-month follow-up. #ASCO23 https://t.co/DP5RvlSYxe pic.twitter.com/rBJ99plopK

— JAMA (@JAMA_current) June 2, 2023

Review | Prevention of venous thromboembolism in patients with cancer

5 Jun, 2023 | 13:48h | UTC

Prevention of venous thromboembolism in patients with cancer – The BMJ

RCT | Osimertinib improves overall survival in resected EGFR-mutated NSCLC, but validity of control group questioned on social media

5 Jun, 2023 | 13:46h | UTC

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter by Dr. Vinay Prasad (recommended – click to see the video)

Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023
38.5% of people who had recurrence got OSI (very low!)
That just isn't good enough
Brain staging is suboptimal= occult met disease
Would you let your mother be on the control arm and not get OSI on progression? pic.twitter.com/CU3jtrvFOj

— Vinay Prasad MD MPH (@VPrasadMDMPH) June 5, 2023